FDA: Bayer Hid Negative Study On Surgery Drug
Bayer acknowledged the omission, and said it was a mistake. The information, it said, was “not shared immediately with the agency because it was preliminary in nature and raised significant questions on the study population, outcomes and methodology.”
Since January, the FDA has been conducting a safety review of Trasylol because of...
To view the full article, register now.